STOCK TITAN

Lantern Pharma: Armistice reports 9.99% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Lantern Pharma Inc. (LTRN) is the issuer whose common stock Armistice Capital, LLC and its managing member Steven Boyd report beneficially owning. As of September 30, 2026, each reports 1,542,681 shares, or 9.99%, with shared voting and dispositive power. The shares are directly held by Armistice Capital Master Fund; Armistice Capital exercises voting and investment power under an Investment Management Agreement, and Boyd may be deemed to beneficially own the shares as Armistice Capital’s managing member.

Beneficially owned shares 1,542,681 shares Reported by Armistice Capital, LLC and Steven Boyd as of September 30, 2026
Percent of class 9.99% Reported by Armistice Capital, LLC and Steven Boyd as of September 30, 2026
beneficially own regulatory
"may be deemed to beneficially own the securities"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
shared voting power regulatory
"Shared voting power: 1,542,681"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared dispositive power: 1,542,681"
Investment Management Agreement regulatory
"pursuant to an Investment Management Agreement"
An investment management agreement is a written contract that hires a professional to make buying, selling and strategy decisions for an investment account or fund, and sets out their duties, fees, risk limits, performance measures and reporting requirements. It matters to investors because the agreement determines who controls the money, how much the service costs, what risks are allowed, and how success or failure is measured—think of it as the service contract that defines expectations and remedies for a hired portfolio manager.
Rule 13d-1(k) regulatory
"Joint Filing Statement pursuant to Rule 13d-1(k)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Lantern Pharma (LTRN) shares did Armistice Capital and Steven Boyd report owning?

Armistice Capital, LLC and Steven Boyd each reported beneficial ownership of 1,542,681 Lantern Pharma common shares, equal to 9.99% of the class, as of September 30, 2026. Both reported shared voting and dispositive power over the shares.

Who directly holds Armistice Capital’s reported Lantern Pharma shares?

Armistice Capital Master Fund is identified as the direct holder. It has the right to receive dividends and sale proceeds; Armistice Capital exercises voting and investment power under an Investment Management Agreement, while Steven Boyd may be deemed to beneficially own the shares as Armistice Capital’s managing member.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





51654W101

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:11/16/2026
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:11/16/2026
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: November 16, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

Keep reading